A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer
Authors:
- Christoph RochlitzCRChristoph Rochlitz
- Jo Ann HorowitzJHJo Ann Horowitz
- Jens SchlegelJSJens Schlegel
- André P. PerruchoudAPAndré P. Perruchoud
- Friedrich KommossFKFriedrich Kommoss
- Christoph T. BolligerCBChristoph T. Bolliger
- Hans-Ulrich KauczorHKHans-Ulrich Kauczor
- Peter DalquenPDPeter Dalquen
- Mary Ann FritzMFMary Ann Fritz
- Steve SwansonSSSteve Swanson
- Richard HerrmannRHRichard Herrmann
- 20 September 1998
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 9 (14) , 2075-2082
Abstract
Mutations of the tumor suppressor gene p53 are the most common genetic alterations observed in human cancer. Loss of wild-type p53 function impairs cell cycle arrest as well as repair mechanisms involved in response to DNA damage. Further, apoptotic pathways as induced by radio- or chemotherapy are also abrogated. Gene transfer of wild-type p53 was shown to reverse these deficiencies and to induce apoptosis in vitro and in preclinical in vivo tumor models. A phase I dose escalation study of a single intratumoral injection of a replication-defective adenoviral expression vector encoding wild-type p53 was carried out in patients with incurable non-small cell lung cancer. All patients enrolled had p53 protein overexpression as a marker of mutant p53 status in pretreatment tumor biopsies. Treatment was performed either by bronchoscopic intratumoral injection or by CT-guided percutaneous intratumoral injection of the vector solution. Fifteen patients were enrolled in two centers, and were treated at four different dose levels ranging from 107 to 1010 PFU (7.5 × 109 to 7.5 × 1012 particles). No clinically significant toxicity was observed. Successful transfer of wild-type p53 was achieved only with higher vector doses. Vector-specific wild-type p53 RNA sequences could be demonstrated in posttreatment biopsies of six patients. Transient local disease control by a single intratumoral injection of the vector solution was observed in four of those six successfully transduced patients. There was no evidence of clinical responses at untreated tumor sites. Wild-type p53 gene therapy by intratumoral injection of a replication-defective adenoviral expression vector is safe, feasible, and biologically effective in patients with advanced non-small cell lung cancer. Gene transfer of the human wild-type (wt) p53 tumor suppressor gene into p53 mutant tumors has been shown to have antiproliferative and apoptotic effects in vitro and in vivo. Schuler et al. report on a phase I clinical study of local wt p53 gene therapy in patients with advanced non-small cell lung cancer. A recombinant replication-deficient adenovirus carrying the complete human wt p53 cDNA under the control of the CMV immediate/early gene promoter was devised as expression vector. Gene transfer was achieved at higher virus doses without occurrence of any relevant treatment-related toxicity. In addition, clinical effects suggestive of a moderate local antiproliferative activity were observed in some patients.Keywords
This publication has 23 references indexed in Scilit:
- Tumor Eradication by Wild-type p53-specific Cytotoxic T LymphocytesJournal of Experimental Medicine, 1997
- An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 1996
- Purification of a Type 5 Recombinant Adenovirus Encoding Human p53 by Column ChromatographyHuman Gene Therapy, 1995
- Modification of Nasal Epithelial Potential Differences of Individuals with Cystic Fibrosis Consequent to Local Administration of a Normal CFTR cDNA Adenovirus Gene Transfer VectorHuman Gene Therapy, 1995
- A Phase 1 Study, in Cystic Fibrosis Patients, of the Safety, Toxicity, and Biological Efficacy of a Single Administration of a Replication Deficient, Recombinant Adenovirus Carrying the cDNA of the Normal Cystic Fibrosis Transmembrane Conductance Regulator Gene in the Lung. National Institutes of Health, Bethesda, MarylandHuman Gene Therapy, 1995
- Cancer statistics, 1994CA: A Cancer Journal for Clinicians, 1994
- Stable Expression of the Wild-Type p53 Gene in Human Lung Cancer Cells after Retrovirus-Mediated Gene TransferHuman Gene Therapy, 1993
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993
- Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumoursNature, 1992
- p53: A Frequent Target for Genetic Abnormalities in Lung CancerScience, 1989